AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2523664 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg twice daily
Number of subjects: 178
Study 2523664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 2523664 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (0.5, 1.25, or 2.5 mg twice daily)
Number of subjects: 178
Study 951465 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg)
Number of subjects: 3
Study 951465 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (320 mg)
Number of subjects: 3
Study 951465 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (320 mg)
Number of subjects: 3
Study 951465 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 3
Study 951465 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 3
Study 31907840 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention spanned both stimuli
Number of subjects: 0
Study 31907840 — intervention group
Group type: COMPARATOR
Intervention: Attention focused on a single object
Number of subjects: 0
Study 31907840 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowed categories to the basic level
Number of subjects: 0
Study 31907840 — intervention group
Group type: EXPERIMENTAL
Intervention: Prioritized object category in distractor's location
Number of subjects: 0
Study 31849032 — intervention group
Group type: EXPERIMENTAL
Intervention: ALO‐02 (20‐160 mg oxycodone)
Number of subjects: 805
Study 31849032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 805
Study 29799344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.1 mg/kg/hr or adjusted to clinical effect)
Number of subjects: 10
Study 29799344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1.0 mg/kg/hr)
Number of subjects: 10
Study 29799344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.85 mg/kg/hr)
Number of subjects: 10
Study 29799344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.70 mg/kg/hr)
Number of subjects: 10
Study 29799344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.55 mg/kg/hr)
Number of subjects: 10
Study 29799344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (any dose)
Number of subjects: 10
Study 27315439 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Sensory High Energy (ESHE)
Number of subjects: 23
Study 27315439 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Sensory Low Energy (ESLE)
Number of subjects: 23
Study 27315439 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Sensory High Energy (LSHE)
Number of subjects: 23
Study 27315439 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Sensory Low Energy (LSLE)
Number of subjects: 23
Study 27315439 — intervention group
Group type: EXPERIMENTAL
Intervention: High Energy (HE) drinks
Number of subjects: 23
Study 27315439 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Sensory (ES) drinks
Number of subjects: 23
Study 27315439 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Sensory High Energy (ESHE) drink
Number of subjects: 23
Study 25087308 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (listening to music during surgery)
Number of subjects: 110
Study 25087308 — intervention group
Group type: COMPARATOR
Intervention: No music therapy (control group)
Number of subjects: 110
Study 22051153 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg, once daily; n = 29)
Number of subjects: 59
Study 22051153 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 30)
Number of subjects: 59
Study 19461428 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate postpartum hemorrhage
Number of subjects: 11323
Study 19461428 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe postpartum hemorrhage
Number of subjects: 11323
Study 19461428 — intervention group
Group type: EXPERIMENTAL
Intervention: Retained placenta
Number of subjects: 11323
Study 19461428 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple pregnancy
Number of subjects: 11323
Study 19461428 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrosomia
Number of subjects: 11323
Study 19461428 — intervention group
Group type: EXPERIMENTAL
Intervention: Episiotomy
Number of subjects: 11323
Study 19461428 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for perineal suture
Number of subjects: 11323
Study 19461428 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced labor
Number of subjects: 11323
Study 17230618 — intervention group
Group type: EXPERIMENTAL
Intervention: subcutaneous rhGH (0.15 IU/kg)
Number of subjects: 48
Study 17230618 — intervention group
Group type: COMPARATOR
Intervention: placebo (menstruum)
Number of subjects: 48
Study 15039245 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 300 mg bupropion (BUP)
Number of subjects: 8
Study 15039245 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (lactose)
Number of subjects: 8
Study 11755834 — intervention group
Group type: EXPERIMENTAL
Intervention: Unoprostone 0.15% twice daily
Number of subjects: 556
Study 11755834 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily
Number of subjects: 556
Study 11755834 — intervention group
Group type: COMPARATOR
Intervention: Betaxolol 0.5% twice daily
Number of subjects: 556
Study 11755834 — intervention group
Group type: COMPARATOR
Intervention: Unoprostone vs Timolol
Number of subjects: 556
Study 11755834 — intervention group
Group type: COMPARATOR
Intervention: Unoprostone vs Betaxolol
Number of subjects: 556
Study 11755834 — intervention group
Group type: EXPERIMENTAL
Intervention: Unoprostone
Number of subjects: 556
Study 11755834 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 556
Study 11755834 — intervention group
Group type: COMPARATOR
Intervention: Betaxolol
Number of subjects: 556
Study 11755834 — intervention group
Group type: COMPARATOR
Intervention: Unoprostone, Timolol, Betaxolol
Number of subjects: 556
Study 10395270 — intervention group
Group type: COMPARATOR
Intervention: Gore-tex grafts (100 grafts)
Number of subjects: 168
Study 10395270 — intervention group
Group type: EXPERIMENTAL
Intervention: Impra grafts (90 grafts)
Number of subjects: 168
Study 10395270 — intervention group
Group type: COMPARATOR
Intervention: Gore-tex grafts
Number of subjects: 168
Study 10395270 — intervention group
Group type: EXPERIMENTAL
Intervention: Impra grafts
Number of subjects: 168
Study 7657769 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 2
Study 7657769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 2565585 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential fatty acid (EFA) supplementation
Number of subjects: 0
Study 1063593 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 6-mercaptopurine and methotrexate maintenance therapy
Number of subjects: 0
Study 1063593 — intervention group
Group type: COMPARATOR
Intervention: Maintenance chemotherapy
Number of subjects: 0
Study 31042340 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental teams with resuscitation-automating devices and goal-directed protocols
Number of subjects: 20
Study 31042340 — intervention group
Group type: COMPARATOR
Intervention: Control teams with standard protocols and equipment
Number of subjects: 20
Study 28387927 — intervention group
Group type: EXPERIMENTAL
Intervention: ITALUNG biomarker panel (IBP)
Number of subjects: 1356
Study 28387927 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal screening (IBP + LDCT)
Number of subjects: 1356
Study 28387927 — intervention group
Group type: COMPARATOR
Intervention: LDCT (Low Dose Computed Tomography)
Number of subjects: 1356
Study 28387927 — intervention group
Group type: COMPARATOR
Intervention: Single test (IBP)
Number of subjects: 1356
Study 25869689 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucomannan (GNN) at a dose of 3 g/day for 3 months
Number of subjects: 0
Study 25869689 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin) at a dose of 3 g/day for 3 months
Number of subjects: 0
Study 23713521 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafluprost 0.0015% (Saflutan®) once daily
Number of subjects: 100
Study 21343386 — intervention group
Group type: EXPERIMENTAL
Intervention: Kneehab (novel garment‐integrated neuromuscular electrical stimulation)
Number of subjects: 96
Study 21343386 — intervention group
Group type: EXPERIMENTAL
Intervention: Polystim (traditional neuromuscular electrical stimulation)
Number of subjects: 96
Study 21343386 — intervention group
Group type: COMPARATOR
Intervention: Control (standard rehabilitation program)
Number of subjects: 96
Study 21343386 — intervention group
Group type: EXPERIMENTAL
Intervention: Kneehab
Number of subjects: 96
Study 21343386 — intervention group
Group type: EXPERIMENTAL
Intervention: Polystim
Number of subjects: 96
Study 21343386 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study 19730234 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass
Number of subjects: 197
Study 19730234 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic adjustable gastric banding
Number of subjects: 197
Study 17160649 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia with bupivacaine and fentanyl
Number of subjects: 50
Study 17160649 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) using morphine
Number of subjects: 50
Study 14985690 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched milk
Number of subjects: 58
Study 14985690 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched yoghurt
Number of subjects: 58
Study 14985690 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched bread
Number of subjects: 58
Study 14985690 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched cereal
Number of subjects: 58
Study 14985690 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched milk and bread
Number of subjects: 58
Study 14985690 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched bread and milk
Number of subjects: 58
Study 11805564 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed technique (electrodes placed through the sacral foramen)
Number of subjects: 6
Study 11805564 — intervention group
Group type: EXPERIMENTAL
Intervention: Open technique (cuff electrodes placed after sacral laminectomy)
Number of subjects: 6
Study 9185038 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 25
Study 9185038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1946567 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory cues of cigarette smoking (with minimal nicotine, 0.5 mg)
Number of subjects: 0
Study 1946567 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoke containing 0.5 mg of nicotine
Number of subjects: 0
Study 1946567 — intervention group
Group type: COMPARATOR
Intervention: Placebo control condition
Number of subjects: 0
Study 6756019 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg morphine administered epidurally
Number of subjects: 45
Study 6756019 — intervention group
Group type: COMPARATOR
Intervention: 2 mg morphine administered epidurally
Number of subjects: 45
Study 6756019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 30755343 — intervention group
Group type: EXPERIMENTAL
Intervention: Crevicular incision with vertical release
Number of subjects: 60
Study 30755343 — intervention group
Group type: COMPARATOR
Intervention: Routine vestibular incision
Number of subjects: 60
Study 29281868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (10 sessions of group therapy)
Number of subjects: 80
Study 29281868 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 25336746 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2765
Study 25336746 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2765
Study 25336746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2765
Study 24893332 — intervention group
Group type: EXPERIMENTAL
Intervention: koumiss + exercise (KE)
Number of subjects: 18
Study 24893332 — intervention group
Group type: COMPARATOR
Intervention: koumiss (K)
Number of subjects: 18
Study 24893332 — intervention group
Group type: COMPARATOR
Intervention: exercise alone (E)
Number of subjects: 18
Study 22691647 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic matrix
Number of subjects: 349
Study 22691647 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemostatic methods (controls)
Number of subjects: 349
Study 22691647 — intervention group
Group type: COMPARATOR
Intervention: Comparison of groups
Number of subjects: 349
Study 22691647 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 349
Study 20207458 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolidine-citrate (1.35% taurolidine and 4% citrate)
Number of subjects: 110
Study 20207458 — intervention group
Group type: COMPARATOR
Intervention: Heparin (5,000 U/mL)
Number of subjects: 110
Study 20207458 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolidine-citrate
Number of subjects: 110
Study 20207458 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 110
Study 18341596 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg daily, given as 50 mg twice daily)
Number of subjects: 661
Study 18341596 — intervention group
Group type: COMPARATOR
Intervention: Acarbose (up to 300 mg daily, given as three equally divided doses)
Number of subjects: 661
Study 18341596 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 661
Study 18341596 — intervention group
Group type: COMPARATOR
Intervention: Acarbose
Number of subjects: 661
Study 18341596 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 661
Study 15974220 — intervention group
Group type: EXPERIMENTAL
Intervention: Battery-powered toothbrush (Oral-B Kids)
Number of subjects: 30
Study 15974220 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 30
Study 12809822 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based survey
Number of subjects: 100
Study 12809822 — intervention group
Group type: COMPARATOR
Intervention: Standard mail survey
Number of subjects: 100
Study 12809822 — intervention group
Group type: COMPARATOR
Intervention: Telephone survey
Number of subjects: 100
Study 10492405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg/ml (300 mg)
Number of subjects: 104
Study 10492405 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 5 mg/ml (200 mg)
Number of subjects: 104
Study 8922653 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 2.5 mg
Number of subjects: 180
Study 8922653 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 5.0 mg
Number of subjects: 180
Study 8922653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 8922653 — intervention group
Group type: COMPARATOR
Intervention: Ibandronate 0.25 mg
Number of subjects: 180
Study 1352717 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM‐CSF
Number of subjects: 14
Study 3993558 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 15
Study 3993558 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15
Study 31353302 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Interscalene Blockade (ISB)
Number of subjects: 129
Study 31353302 — intervention group
Group type: COMPARATOR
Intervention: Single-injection ISB
Number of subjects: 129
Study 31353302 — intervention group
Group type: COMPARATOR
Intervention: Local Infiltration Analgesia
Number of subjects: 129
Study 31353302 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ISB
Number of subjects: 129
Study 29405507 — intervention group
Group type: COMPARATOR
Intervention: Sham pill described as 'a well‐known tablet available without prescription'
Number of subjects: 203
Study 26758502 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (5 ml/d, 1.2 g/d n-3 long-chain PUFA)
Number of subjects: 115
Study 26758502 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation
Number of subjects: 115
Study 26758502 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (SO) supplementation
Number of subjects: 115
Study 25452376 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention of syndesmotic screw
Number of subjects: 51
Study 25452376 — intervention group
Group type: COMPARATOR
Intervention: Removal of syndesmotic screw
Number of subjects: 51
Study 22565140 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 22565140 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 20597040 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered pump spray application of nasal steroid
Number of subjects: 11
Study 20597040 — intervention group
Group type: COMPARATOR
Intervention: Inhalation using the Pari sinus device
Number of subjects: 11
Study 17905165 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs) - either rosiglitazone or pioglitazone
Number of subjects: 20191
Study 17905165 — intervention group
Group type: COMPARATOR
Intervention: Control (comparators)
Number of subjects: 20191
Study 16230896 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-preserving amplification
Number of subjects: 0
Study 16230896 — intervention group
Group type: COMPARATOR
Intervention: Non-phase-preserving amplification
Number of subjects: 0
Study 16230896 — intervention group
Group type: EXPERIMENTAL
Intervention: Both amplification types
Number of subjects: 0
Study 12171453 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient‐dense protein‐energy liquid supplement and encouragement to improve intake from other foods
Number of subjects: 83
Study 12171453 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study 10546234 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis patients
Number of subjects: 44
Study 10546234 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis patients with at least one vertebral fracture
Number of subjects: 44
Study 10546234 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 male patients with monoclonal gammopathy of undetermined significance)
Number of subjects: 44
Study 7538403 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 6 U/day subcutaneously
Number of subjects: 15
Study 7538403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2073488 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid clonidine (150 micrograms)
Number of subjects: 36
Study 2073488 — intervention group
Group type: COMPARATOR
Intervention: Oral diazepam (10 mg)
Number of subjects: 36
Study 6778335 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment including myringotomy and aeration tube insertion
Number of subjects: 0
Study 6778335 — intervention group
Group type: COMPARATOR
Intervention: Nonadenoidectomy
Number of subjects: 0
Study 31765383 — intervention group
Group type: EXPERIMENTAL
Intervention: Household sanitation facility use
Number of subjects: 4104
Study 31765383 — intervention group
Group type: EXPERIMENTAL
Intervention: School sanitation coverage > 3 toilets per 100 pupils
Number of subjects: 4104
Study 31765383 — intervention group
Group type: EXPERIMENTAL
Intervention: Village sanitation coverage > 81%
Number of subjects: 4104
Study 31765383 — intervention group
Group type: EXPERIMENTAL
Intervention: General contextual effects from village and school domains
Number of subjects: 4104
Study 31765383 — intervention group
Group type: COMPARATOR
Intervention: School sanitation
Number of subjects: 4104
Study 31765383 — intervention group
Group type: COMPARATOR
Intervention: Village sanitation
Number of subjects: 4104
Study 28802789 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine
Number of subjects: 64
Study 28802789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 26509673 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg)
Number of subjects: 14
Study 22858209 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor analysis and cluster analysis conducted on all subjects using Young Mania Rating Scale and Montgomery‐Åsberg Depression Scale.
Number of subjects: 2179
Study 22858209 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis conducted separately for DSM-IV mixed episodes (n=644) and non-mixed episodes (n=1535).
Number of subjects: 2179
Study 21211004 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg body weight)
Number of subjects: 30
Study 21211004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21211004 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPD1 34C > T variant
Number of subjects: 30
Study 21211004 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS (2 ng/kg E. Coli LPS)
Number of subjects: 30
Study 19122556 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 2 microg kg(‐1) (group R)
Number of subjects: 105
Study 19122556 — intervention group
Group type: COMPARATOR
Intervention: sufentanil 0.2 microg kg(‐1) (group S)
Number of subjects: 105
Study 17223209 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma apelin levels in IDC patients (median 26.5 pg/ml, range <3.40-97.6 pg/ml)
Number of subjects: 65
Study 17223209 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP, IL‐6, TNF‐alpha, norepinephrine levels
Number of subjects: 65
Study 15587238 — intervention group
Group type: EXPERIMENTAL
Intervention: Smith Irrational Beliefs Inventory
Number of subjects: 1851
Study 15587238 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor analyses (alpha factoring, direct oblimin rotation)
Number of subjects: 1851
Study 11553198 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 517
Study 11553198 — intervention group
Group type: COMPARATOR
Intervention: NPH
Number of subjects: 517
Study 9671087 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compression‐decompression (ACD) CPR
Number of subjects: 576
Study 9671087 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR (STD-CPR)
Number of subjects: 576
Study 8138958 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (20, 40 and 60 mg)
Number of subjects: 6